Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032422 | 1.00 | USP30 (0.53) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL1032423 | 1.00 | USP30 (0.53) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL2774486 | 0.93 | ALDH1A1 (0.56) | USP30SYKDDB1CRBNALDH1A1 | |
| SCHEMBL596064 | 0.87 | USP30 (0.54) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL28911208 | 0.87 | USP30 (0.54) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL23292281 | 0.87 | USP30 (0.54) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL529343 | 0.87 | USP30 (0.54) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL595857 | 0.87 | USP30 (0.54) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL22895552 | 0.87 | USP30 (0.54) | USP30SYKPIK3CDDDB1CRBN | |
| SCHEMBL23292407 | 0.86 | USP30 (0.53) | USP30SYKPIK3CDDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| EP-4574822-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| CN-118702672-A | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-115335050-B | Compounds and compositions for treating skin disorders | 卡玛瑞制药有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2024-04-18 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| CN-115335050-A | Compounds and compositions for treating skin conditions | 卡玛瑞制药有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2021154966-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | KAMARI PHARMA LTD. (IL) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | USP30 2986/4885SYK 2348/4885PIK3CD 4429/4885 |
| US-20240124413-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | USP30 2986/4885SYK 2348/4885PIK3CD 4429/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | USP30 2986/4885SYK 2348/4885PIK3CD 4429/4885 |
| US-20220332697-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | RDX, HAX1, F12 | USP30 2986/4885SYK 2348/4885PIK3CD 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.